Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Brazil
  4. Bolsa de Valores de Sao Paulo
  5. Ouro Fino Saúde Animal Participações S.A.
  6. News
  7. Summary
    OFSA3   BROFSAACNOR7

OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES S.A.

(OFSA3)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Ouro Fino Saúde Animal Participações S A : Notice to the Market - Possibility of producing a vaccine against Covid

07/28/2021 | 11:26am EST

OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES S.A.

Taxpayers' Registry (CNPJ/MF) No. 20.258.278/0001-70

Board of Trade Registry (NIRE) No. 35.300.465.415

NOTICE TO THE MARKET

OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES S.A. ("Company"), in continuity with the response to Official Letter No. 529/2021-SLS, issued by B3 - Brasil, Bolsa, Balcão ("B3") on April 20, 2021 and the Notice to the Market on May 19, 2021, hereby announces to its shareholders and to the market in general that the Company maintains no changes in the progress of matterss involving the possible production of vaccines against COVID-19, despite news published in the media about this subject.

Therefore, the Company reiterates that it remains wihtout sufficient and relevant information, data, characteristics and assessments of regulatory issues and investments on the subject that may impact an investor's decision to trade shares issued by it, and also states that its only official channel of information to the market on this matter is through its Investor Relations department.

Thus, the Company reinforces that it continues with its strategic planning focused on developing its product pipeline, which includes veterinary vaccines, and keeping its shareholders and the market in general duly informed of any developments in relation to this notice.

Cravinhos, July 28th, 2021.

MARCELO DA SILVA

Chief Finance and Investor Relations Officer

Disclaimer

Ourofino Saúde Animal Participações SA published this content on 28 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2021 15:23:16 UTC.


© Publicnow 2021
All news about OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES S.A.
11/18OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES : Material Fact - 11/18/2021
PU
11/11Ouro Fino Sa?de Animal Participa?es S.A. Reports Earnings Results for the Third Quarter..
CI
08/17OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES : Institutional Presentation
PU
08/05Ouro Fino Saúde Animal Participações S.A. Reports Earnings Results for the Second Quart..
CI
07/28OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES : Notice to the Market - Possibility of producing a v..
PU
07/21OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES : Notice to the Market - Resignation of a member of t..
PU
05/06Ouro Fino Saúde Animal Participações S.A. Reports Earnings Results for the First Quarte..
CI
01/29OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES : Material Fact - 01/29/2021
PU
2020OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES : Institutional Presentation
PU
2020OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES : Notice to Shareholders - Distribution of Dividends
PU
More news
Financials
Sales 2021 792 M 139 M 139 M
Net income 2021 80,4 M 14,1 M 14,1 M
Net Debt 2021 225 M 39,5 M 39,5 M
P/E ratio 2021 16,8x
Yield 2021 1,88%
Capitalization 1 348 M 237 M 237 M
EV / Sales 2021 1,99x
EV / Sales 2022 1,84x
Nbr of Employees 1 300
Free-Float 31,5%
Chart OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES S.A.
Duration : Period :
Ouro Fino Saúde Animal Participações S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES S.A.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 25,01 BRL
Average target price 35,50 BRL
Spread / Average Target 41,9%
EPS Revisions
Managers and Directors
Kleber Cesar Silveira Gomes Chief Executive Officer
Marcelo da Silva Chief Financial & Investor Relations Officer
Jardel Massari Chairman
Luiz Antônio Santos Baptista Independent Director
Márcio Guedes Pereira Independent Director
Sector and Competitors